Now livetag icon
2026 State of Ecommerce: Own the AI Shopper Journey.Download Reportbanner icon
Sumitomo Pharma Co., Ltd.

August 2026

  • Home
  • Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd. Market Share Analysis for August 2026

Sumitomo Pharma Company Limited is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka.
Year Founded2005
Employees1001 - 5000
Annual Revenue> $1B
sumitomo-pharma.com
Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. (including company regionals)
  • sumitomo-pharma.com
    sumitomo-pharma.com
See more website traffic and engagement information

Sumitomo Pharma Co., Ltd. Revenue up to August 2026 is > 1B

revenue generated by Sumitomo Pharma Co., Ltd. top domains

Sumitomo Pharma Co., Ltd. top domains revenue over 3 years

Revenue for Sumitomo Pharma Co., Ltd. top domains

sumitomo-pharma.comsumitomo-pharma.com> 1B
See more with Sales Intelligence

Total visits to Sumitomo Pharma Co., Ltd.'s top domains

Understand Sumitomo Pharma Co., Ltd. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown
sumitomo-pharma.comsumitomo-pharma.com17.7K
See more with Sales Intelligence

Avg. visit duration in Sumitomo Pharma Co., Ltd.'s top domains

Analyze Sumitomo Pharma Co., Ltd. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown
sumitomo-pharma.comsumitomo-pharma.com00:00:34
See more with Sales Intelligence

Avg. pageviews on Sumitomo Pharma Co., Ltd.'s top domains

See how Sumitomo Pharma Co., Ltd. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown
sumitomo-pharma.comsumitomo-pharma.com1.85
See more with Sales Intelligence

Want to gain deeper traffic insights?

Filter 20.3M+ online businesses. Discover new leads when their traffic spikes, when they start or stop using technologies, or when they get positive press.


Sumitomo Pharma Co., Ltd. top competitors by domain

Top similar sites in August 2026, ranked by their affinity

Benchmark Your Digital Performance

Identify high-value opportunities, track your performance, and win your market.


Top technologies used by Sumitomo Pharma Co., Ltd.

These are the website technologies, by industry, used by Sumitomo Pharma Co., Ltd. top domains

Conversion & Analytics (5)

Google Analytics

Google Analytics

eCommerce (2)

Vtex Enterprise

Vtex Enterprise

Marketing (2)

Google Marketing Platform

Google Marketing Platform

Mobile (2)

Meta Viewport

Meta Viewport

More Technologies

5

See all

Ready to discover high quality prospects?

Identify what technologies a website uses to craft the perfect sales pitch, and shorten the sales cycle with the Similarweb Sales Intelligence Solution.


News & Signals from Sumitomo Pharma Co., Ltd.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSumitomo Pharma Co. is developing DSP-3077 on Mar 1st '26.Sumitomo Pharma America and Sumitomo Pharma are developing DSP-3077 in collaboration with Racthera and S-Racmo as part of ongoing work to advance retinal regenerative therapies.
NewsSumitomo Pharma Co., Ltd received award 10th Japan Bioindustry Award on Jul 15th '26.Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Toru Kimura; "Sumitomo Pharma") and RACTHERA Co., Ltd. (Head Office: Chuo-ku, Tokyo, Japan; President and CEO: Atsushi Ikeda; "RACTHERA") announced today that the development of AMCHEPRY(R)(the "Product"), the allogeneic iPS cell-derived dopaminergic neural progenitor cell product resulting from joint research with Kyoto University, has received the 10th Japan Bioindustry Award from the Japan Bioindustry Association (JBA).
NewsSumitomo Pharma Co., Ltd attended event EHA 2026 on Jun 11th '26.Sumitomo Pharma America announces encouraging clinical and translational data at EHA 2026, highlighting investigational combination therapy in relapsed/refractory Myelofibrosis and new research findings in menin Inhibition in leukemia.

See all Sumitomo Pharma Co., Ltd. signals

Focus your sales teams on the most promising opportunities. By prioritizing opportunities and engaging at the right time, you can optimize efforts and close more deals.